title: EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.
abstract: OBJECTIVE
  To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO).
  
  
  METHODS
  A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9.
  
  
  RESULTS
  The average change of best-corrected visual acuity from baseline to Month 9 was 17.83 ± 10.89 letters in BRVO and 14.23 ± 11.74 letters in CRVO. The change in best-corrected visual acuity was not statistically different between the groups (P = 0.216). The mean reduction of central retina thickness from baseline to Month 9 was 289.97 ± 165.42 μm and 420.47 ± 235.89 μm in BRVO and CRVO, respectively. The mean numbers of injections was 7.14 ± 1.90 in BRVO and 7.59 ± 1.39 in CRVO from baseline to Month 9 (P = 0.4705). There were 7 serious adverse events (SAEs) in 5 patients (8.33%, 2 BRVO and 3 CRVO). All the SAEs were nonocular and were not related to the drug or the injection procedure.
  
  
  CONCLUSIONS
  Intravitreal injections of conbercept demonstrated a generally favorable safety and tolerability profile as well as efficacy in the treatment of macular edema due to RVO.
authors.affiliation: *Department of Retina, The Affiliated Eye Hospital, Wenzhou Medical University, Wenzhou, China; †Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Peking, China; ‡Department of innovated Medicine, Chengdu Kanghong Biotechnology, Inc, Chengdu, China; §Department of clinical research, Chengdu Kanghong Biotechnology, Inc, Chengdu, China; and ¶Chengdu Kanghong Pharmaceutical Group, Chengdu Kanghong Biotechnology, Inc, Chengdu, China.
authors.forename: Zuhua
authors.initials: Z
authors.lastname: Sun
authors.forename: Haiying
authors.initials: H
authors.lastname: Zhou
authors.forename: Bing
authors.initials: B
authors.lastname: Lin
authors.forename: Xuan
authors.initials: X
authors.lastname: Jiao
authors.forename: Yingdong
authors.initials: Y
authors.lastname: Luo
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Shanshan
authors.initials: S
authors.lastname: Tao
authors.forename: Quan
authors.initials: Q
authors.lastname: Wu
authors.forename: Zunhong
authors.initials: Z
authors.lastname: Ke
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Liu
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D065228:Non-Randomized Controlled Trials as Topic; D011446:Prospective Studies; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000150:complications*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C527363:KH902 fusion protein